30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

3Q13 Revenue: Seikagaku

(For FY2Q13 ended 9/30/13; notes pertain to 1HFY13)

¥7,758MM (~US $78.6MM), +19%

  • Growth supported by ex-domestic sales of Gel-One injectable for knee osteoarthritis pain
  • In 4Q, Genzyme filed an appeal in the Gel-One patent infringement suit; expecting no impact on sales
  • U.S. SUPARTZ injectable sale-s fell slightly due to reimbursement restrictions, while sales of ARTZ to China continue to develop favorably